Pernix Therapeutics to Present at the 25th Annual ROTH Growth Conference 25th Annual ROTH Conference Business Wire THE WOODLANDS, Texas -- March 11, 2013 Pernix Therapeutics Holdings, Inc. (NASDAQ: PTX), a specialty pharmaceutical company, today announced that Cooper Collins, President and Chief Executive Officer, will present at the 25^th Annual ROTH Growth Stock Conference on Tuesday, March 19, 2013 at 9:30 a.m. PDT. The conference will be held at The Ritz Carlton in Dana Point, CA. The presentation will be broadcast live over the Internet and can be accessed on the Company’s website, www.pernixtx.com, under “Webcasts and Presentation” on the investor relations section. The audio-recording of the presentation will be archived on the Company’s website for approximately 30 days following the conclusion of the presentation. About Pernix Therapeutics Holdings, Inc. Pernix Therapeutics is a specialty pharmaceutical company primarily focused on the sales, marketing, manufacturing and development of branded, generic and OTC pharmaceutical products. The Company manages a portfolio of branded products, including the recently acquired Hawthorn Pharmaceuticals’ product line. The Company’s branded products for the pediatrics market include CEDAX®, an antibiotic for middle ear infections, NATROBA™, a topical treatment for head lice marketed under an exclusive co-promotion agreement with ParaPRO, LLC, and a family of treatments for cough and cold (ZUTRIPRO®, BROVEX®, ALDEX® and PEDIATEX®). The Company’s branded products for gastroenterology include OMECLAMOX-PAK®, a 10-day treatment for H. pylori infection and duodenal ulcer disease, and REZYST™, a probiotic blend to promote dietary management. The Company promotes its branded pediatric and gastroenterology products through its sales force. Pernix markets its generic products through its wholly-owned subsidiaries, Cypress Pharmaceutical and Macoven Pharmaceuticals. The Company’s wholly-owned subsidiary, Great Southern Laboratories, manufactures and packages products for the pharmaceutical industry in a wide range of dosage-forms. A product candidate utilizing cough-related intellectual property is in development for the U.S. OTC market. Founded in 1996, the Company is based in The Woodlands, TX. Additional information about Pernix is available on the Company’s website located at www.pernixtx.com. Contact: Pernix Therapeutics Holdings, Inc. Joseph T. Schepers, 800-793-2145 ext. 3002 Director, Investor Relations email@example.com
Russian International Reserves Fall $15.7 Billion in Week to Dec. 19
Pernix Therapeutics to Present at the 25th Annual ROTH Growth Conference
Press spacebar to pause and continue. Press esc to stop.